Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573171 | 0.94 | NR1H4 (0.42) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL1573416 | 0.94 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL13918694 | 0.93 | ALDH1A1 (0.38) | MEN1KMT2ATAAR1ALDH1A1HPGD | |
| SCHEMBL1573019 | 0.93 | PLK1 (0.38) | MEN1KMT2AALDH1A1NR1H4HPGD | |
| SCHEMBL1573349 | 0.92 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL1573017 | 0.92 | F10 (0.39) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL13918726 | 0.91 | F10 (0.38) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL13918698 | 0.90 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1HPGDNPSR1 | |
| SCHEMBL1572822 | 0.90 | F10 (0.38) | MEN1KMT2AALDH1A1AKR1C2AKR1C1 | |
| SCHEMBL150004 | 0.89 | MAPT (0.46) | MEN1KMT2AALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | claimed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | claimed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | MEN1 621/4885KMT2A 3395/4885TAAR1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.